Payment overview · 2025
General Payments
$552.89
30 reported records · 15 companies
Healthcare provider profile · identity verified
Donald K Huffman, DO
Allopathic & Osteopathic Physicians|General Practice · JEFFERSON, NC · NPI 1689201691
Verified facts
What the public records show
CMS Open Payments records show Donald K Huffman, DO received $552.89 in general payments during 2025 across 30 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $95.56 | 17.3% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $81.10 | 14.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.65 | 9.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.94 | 8.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.83 | 7.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.71 | 7.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.17 | 5.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.82 | 5.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.26 | 4.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.73 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.13 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.10 | 3.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.66 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.40 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.83 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.89 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $95.56 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $81.10 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.65 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.94 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.71 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.17 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.58 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 55 |
| Losartan Potassium | Losartan Potassium | 140 | 53 |
| Trazodone Hcl | Trazodone Hcl | 126 | 41 |
| Gabapentin | Gabapentin | 120 | 42 |
| Lisinopril | Lisinopril | 116 | 52 |
| Prednisone | Prednisone | 115 | 95 |
| Tramadol Hcl | Tramadol Hcl | 115 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 39 |
| Omeprazole | Omeprazole | 108 | 40 |
| Famotidine | Famotidine | 102 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 93 | 40 |
| Eliquis | Apixaban | 89 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 40 |
| Sertraline Hcl | Sertraline Hcl | 67 | 25 |
| Furosemide | Furosemide | 65 | 26 |
| Metformin Hcl | Metformin Hcl | 65 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 19 |
| Simvastatin | Simvastatin | 56 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 45 |
| Metformin Hcl Er | Metformin Hcl | 47 | 15 |
| Ozempic | Semaglutide | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Mupirocin | Mupirocin | 42 | 28 |
| Potassium Chloride | Potassium Chloride | 42 | 19 |
| Alprazolam | Alprazolam | 40 | 12 |
| Finasteride | Finasteride | 40 | 15 |
| Jardiance | Empagliflozin | 40 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 23 |
| Ondansetron Odt | Ondansetron | 35 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 20 |
| Buspirone Hcl | Buspirone Hcl | 34 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Spironolactone | Spironolactone | 34 | 13 |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Sucralfate | Sucralfate | 31 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 13 |
| Azithromycin | Azithromycin | 29 | 25 |
| Fluconazole | Fluconazole | 29 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 17 |
| Meloxicam | Meloxicam | 28 | 14 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 12 |
| Nystatin | Nystatin | 21 | 16 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 15 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 17 | 15 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.89 · 30 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AREXVY, CAPLYTA, Cologuard Collection Kit, Dyanavel XR, IBSRELA, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error